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subject presenting reat technical promise but sub- 
ject to considerable hyperbole. This book is a 
sober articulate statement which points the way 
forward, defining interdisciplinary opportunities 
without minimising the complexity and difficulties 
such scientific interaction will bring. 
D. Ganderton 
Receptor Binding in Drug Research (Clinical Pharmacology, 
Vol. 6) 
Edited by Robert  A. O 'Br ien  
Marcel Dekker; New York, 1986 
xx + 519 pages. USA and Canada $89.75; elsewhere $107.50 
In the Foreword to this book it is suggested that 
'binding techniques.., are now truly relevant o the 
needs of mankind'.  However, there can be no 
doubt that receptor binding as a methodology has 
become a 'mature'  science and an accepted way of 
life in drug research. It is a commercially viable 
technique and this text reflects such a drug 
development perspective. The coverage of this vast 
literature is not all-inclusive, as th~ Editor's stated 
intention is '... to present some philosophies for 
use of receptor pharmacology ... in some of the 
most challenging therapeutic areas'. 
The text is divided into five sections. Part I con- 
tains two chapters; one on methodology and 
analysis, and the second on computer analysis. 
Both are well written and would appear to provide 
an excellent introduction to problems and con- 
siderations required in receptor binding studies. 
Whether there is sufficiently in depth information 
in this section to interest he committed 'binder' I
cannot judge. 
The next three sections are devoted to receptor 
screening as applied to (Part II) specific 
therapeutic areas, (Part III) multiple therapeutic 
areas, and (Part IV) peptides, growth factors and 
endogenous ligands. Specific therapies include the 
benzodiazepines, neuroleptics, antidepressants, 
psychomotor stimulants and the opiates. Recep- 
tors with multiple therapeutic implications are 
those for leukotrienes, purines, steroid hormones, 
calcium and muscarinic cholinergic compounds. 
The third of these sections deals with receptors for 
interferon, platelet-derived growth factor, insulin 
and cholecystokinin. Although each chapter pro- 
vides a brief review of the literature, most of the 
text deals with the techniques and the conditions 
required for the particular assay(s) in question. 
Some chapters focus more on methodological 
development (muscarinic cholinergic receptors); 
while, others provide more information on drug 
actions in well established binding protocols. In- 
dividually the chapters are interesting and infor- 
mative, but the format is so repetitive that I found 
it difficult to maintain the necessary concen- 
tration. 
The last chapter in Part IV and all of Part V deal 
with receptor methodologies for identifying en- 
dogenous ligands and new drugs especially an- 
tidepressants, anxiolytics and cholinergic agents. 
Chapter 19 describes attempts and failure to iden- 
tify a benzodiazepine ligand isolated from human 
serum. The authors highlight he problems and pit- 
falls they encountered and by doing so emphasize 
most effectively the need for adequate controls and 
for structural analysis of suspected ligands. Final- 
ly, in the section on drug development there is a 
very interesting discussion of the importance of 
considering possible interactions of a drug with 
more than one receptor system. Binding studies 
generally seem to focus on one receptor, ignoring 
or overlooking possible multiple activities of a 
drug. Yet the importance of such considerations i  
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emphasised in the chapter on antidepressants, 
where the succes of studying such drug interactions 
with multiple drug receptor systems was not in 
predicting the antidepressant potency, but the 
possible side effects. 
The book is well presented and achieves the 
Editor's aims in many of the chapters. Whether 
these areas of receptor binding are truly at the 
frontier of future drug development only time can 
tell. But as a reference for those not directly in- 
volved in the field or for other 'binders' to see 
what is going on in various areas of therapeutic in- 
terest, this must be a useful, but expensive source. 
R. Bruce Holman 
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